-
Rob Reiner murder: son not medically cleared for court
-
FIFA announces $60 World Cup tickets for 'loyal fans'
-
Dembele and Bonmati scoop FIFA Best awards
-
Shiffrin dominates first run in Courchevel slalom
-
EU weakens 2035 combustion-engine ban to boost car industry
-
Arctic sees unprecedented heat as climate impacts cascade
-
French lawmakers adopt social security budget, suspend pension reform
-
Afrikaners mark pilgrimage day, resonating with their US backers
-
Lawmakers grill Trump officials on US alleged drug boat strikes
-
Hamraoui loses case against PSG over lack of support after attack
-
Trump - a year of ruling by executive order
-
Iran refusing to allow independent medical examination of Nobel winner: family
-
Brazil megacity Sao Paulo struck by fresh water crisis
-
Australia's Green becomes most expensive overseas buy in IPL history
-
VW stops production at German site for first time
-
Man City star Doku sidelined until new year
-
Rome's new Colosseum station reveals ancient treasures
-
EU eases 2035 combustion-engine ban to boost car industry
-
'Immense' collection of dinosaur footprints found in Italy
-
US unemployment rises further, hovering at highest since 2021
-
Senators grill Trump officials on US alleged drug boat strikes
-
Filmmaker Rob Reiner's son to be formally charged with parents' murder
-
Shift in battle to tackle teens trapped in Marseille drug 'slavery'
-
Stocks retreat on US jobs, oil drops on Ukraine hopes
-
Manchester United 'wanted me to leave', claims Fernandes
-
Serbian President blames 'witch hunt' for ditched Kushner hotel plan
-
Man who hit Liverpool parade jailed for over 21 years
-
Sahel juntas would have welcomed a coup in Benin: analysts
-
PSG ordered to pay around 60mn euros to Mbappe in wage dispute
-
BBC says will fight Trump's $10 bn defamation lawsuit
-
Stocks retreat ahead of US jobs, oil drops on Ukraine hopes
-
Suicide bomber kills five soldiers in northeast Nigeria: sources
-
EU set to drop 2035 combustion-engine ban to boost car industry
-
Australia's Green sold for record 252 mn rupees in IPL auction
-
Elusive December sun leaves Stockholm in the dark
-
Brendan Rodgers joins Saudi club Al Qadsiah
-
Thailand says Cambodia must announce ceasefire 'first' to stop fighting
-
M23 militia says to pull out of key DR Congo city at US's request
-
Thousands of glaciers to melt each year by mid-century: study
-
China to impose anti-dumping duties on EU pork for five years
-
Nepal starts tiger census to track recovery
-
Economic losses from natural disasters down by a third in 2025: Swiss Re
-
Indonesians reeling from flood devastation plea for global help
-
Timeline: How the Bondi Beach mass shooting unfolded
-
On the campaign trail in a tug-of-war Myanmar town
-
Bondi Beach suspect visited Philippines on Indian passport
-
Kenyan girls still afflicted by genital mutilation years after ban
-
Djokovic to warm up for Australian Open in Adelaide
-
Man bailed for fire protest on track at Hong Kong's richest horse race
-
Men's ATP tennis to apply extreme heat rule from 2026
| SCS | 0.12% | 16.14 | $ | |
| CMSC | -0.06% | 23.286 | $ | |
| JRI | -0.33% | 13.515 | $ | |
| CMSD | -0.09% | 23.345 | $ | |
| GSK | -1.05% | 48.73 | $ | |
| BCC | 0.92% | 76.03 | $ | |
| NGG | -0.45% | 75.69 | $ | |
| RYCEF | -0.68% | 14.8 | $ | |
| RIO | 0.41% | 76.13 | $ | |
| RELX | -0.61% | 40.83 | $ | |
| BCE | -0.49% | 23.495 | $ | |
| VOD | 0.04% | 12.705 | $ | |
| BTI | -0.69% | 57.342 | $ | |
| AZN | -0.86% | 90.775 | $ | |
| RBGPF | 4.1% | 81 | $ | |
| BP | -4.21% | 33.825 | $ |
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy (SNAP-TI) platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Further, it has license, research and development, and collaboration agreements with OUI, NIH, CanSino, CRUK; and Arbutus.
Event: Q1 Investor Summit
Presentation Time: 11:00 AM ET
Location: https://www.webcaster4.com/Webcast/Page/3082/52091
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who are significantly undervalued and have a near-term catalyst.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
Access Newswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESS Newswire
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Barinthus Biotherapeutics plc
View the original press release on ACCESS Newswire
R.Chavez--AT